Want to join the conversation?
Celgene International Sarl, a subsidiary of $CELG, said it will present phase 1b study data evaluating effects of investigational oral GED-0301 (mongersen) on both endoscopic response and clinical remission in patients with active Crohn's disease. Crohn's disease is an immune-mediated, chronic inflammatory condition of the gastrointestinal tract.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.